Several clinical trials of NASH indicated that PPAR agonists may improve steatosis, inflammation and fibrosis (Ratziu et al., 2016; Gawrieh et al., 2021). The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatohepatitis.